Dr. Ornstein on antibody-drug conjugates for immunotherapy-refractory urothelial carcinoma

Treatment with nadofaragene led to a complete response rate of 75% at 3 months.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.

A lookahead of the notable FDA decisions and conferences slated for Q2 2025.